You are here
Advisory EditorImmunotherapy with nivolumab and pembrolizumab or a combination therapy have shown improvements in the survival of patients with squamous non-small-cell lung cancer. With many immunotherapeutic agents in the developmental phase, assigning patients to the best therapy will become ever more important and challenging.
Advisory EditorBiomarker testing has opened the door for precision medicine based on an individual patient’s tumor characteristics rather than histology alone. Key biomarkers in patients with advanced non-small-cell lung cancer are epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, KRAS mutations or programmed death-ligand 1 (PD-L1) expression. Limitations to this approach, e.g. the sensitivity of the diagnostic tools or tissue availability, should be overcome by modern molecular technologies.
- In this video, Martin Reck, Head of the Oncology unit, LungenClinic Grosshansdorf, Germany, discusses the emergence of immunotherapy and the positive results of four randomized trials on immunotherapy vs. chemotherapy, showing benefit in overall survival. He also mentions that immunotherapy might work better than chemotherapy in selected patients and reviews treatment options for a specific population of patients with autoimmune diseases at baseline.
- Therapy of EGFR-mutated lung cancer was discussed in detail during the World Conference on Lung Cancer held in Vienna, including recent data. Federico Cappuzzo, Director Medical Oncology Department at Ospedale Civile, Livorno, Italy, provides insights into the management of EGFR-mutated NSCLC with the new molecule osimertinib and reviews the benefits and limitations of liquid biopsy.
- This session focuses on the overall landscape of ALK inhibitors for treatment of NSCLC. Enriqueta Felip, Head of the Medical Oncology Service of the Thoracic Tumors Committee, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the various ALK inhibitors currently available, including crizotinib, ceritinib and alectinib, as well as the possible treatment modalities with these drugs either as monotherapy or in combination. She also provides a brief overview of the various randomized trials which have shown positive results with these inhibitors and stresses the need for further trials in order to obtain more data in this area.
Managing EditorThe regulation of tobacco control, immunotherapy, and targeted therapy in ALK- and KRAS-rearranged lung cancer were some of the highlights at the World Conference on Lung Cancer 2016 in Vienna, says Dr. Zimmermann, Senior Resident in Medical Oncology at Fribourg Hospital, Switzerland. He and the other editors of the Resource Centre “Milestones in non-small-cell lung cancer” invite you to visit this platform to keep abreast of recent scientific developments in this area.
Editor in ChiefThe Resource Centre “Milestones in non-small-cell lung cancer” owes its title to the tremendous progress that has been made in the treatment of advanced non-small-cell lung cancer with targeted therapy and immunotherapy. Remaining knowledge gaps include the approach to take in patients insensitive to immunotherapy as well as the lack of standardization with regard to trial strategy and design. This interview with Prof. Solange Peters, Medical Oncology Service Chief, Oncology Department, University Hospital of Lausanne, Switzerland, reviews these topics.